Multi-target combinatory strategy to overcome tumor immune escape

Yu, Yingyan

doi:10.1007/s11684-022-0922-5

Cited by 15 publications

(5 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ipilimumab treatment of melanoma prolongs patients’ survival by 4 months ( 84 ). In 2011, the FDA approved ipilimumab for the treatment of advanced melanoma ( 85 ), which opened a new era of immunotherapy in cancer treatment.…”

Section: Icismentioning

confidence: 99%

Frontiers and future of immunotherapy for pancreatic cancer: from molecular mechanisms to clinical application

Zheng,

Liu,

Zhang

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

Pancreatic cancer is a highly aggressive malignant tumor, that is becoming increasingly common in recent years. Despite advances in intensive treatment modalities including surgery, radiotherapy, biological therapy, and targeted therapy, the overall survival rate has not significantly improved in patients with pancreatic cancer. This may be attributed to the insidious onset, unknown pathophysiology, and poor prognosis of the disease. It is therefore essential to identify and develop more effective and safer treatments for pancreatic cancer. Tumor immunotherapy is the new and fourth pillar of anti-tumor therapy after surgery, radiotherapy, and chemotherapy. Significant progress has made in the use of immunotherapy for a wide variety of malignant tumors in recent years; a breakthrough has also been made in the treatment of pancreatic cancer. This review describes the advances in immune checkpoint inhibitors, cancer vaccines, adoptive cell therapy, oncolytic virus, and matrix-depletion therapies for the treatment of pancreatic cancer. At the same time, some new potential biomarkers and potential immunotherapy combinations for pancreatic cancer are discussed. The molecular mechanisms of various immunotherapies have also been elucidated, and their clinical applications have been highlighted. The current challenges associated with immunotherapy and proposed strategies that hold promise in overcoming these limitations have also been discussed, with the aim of offering new insights into immunotherapy for pancreatic cancer.

show abstract

Section: Icismentioning

confidence: 99%

Frontiers and future of immunotherapy for pancreatic cancer: from molecular mechanisms to clinical application

Zheng,

Liu,

Zhang

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…306 Similar hepatic and immune-related adverse events were also observed in combined treatment with ICBs in melanoma. [334][335][336] These described studies imply that a combination with ICB can improve therapeutic outcomes for therapy-resistant patients compared with either therapy alone. The clinical feasibility of the combined strategy warrants further exploration, and the safety profile should be carefully documented.…”

Section: With Immune Checkpoint Blockade (Icb)mentioning

confidence: 99%

Tumor cell plasticity in targeted therapy-induced resistance: mechanisms and new strategies

Pang

Yang

et al. 2023

Sig Transduct Target Ther

View full text Add to dashboard Cite

Despite the success of targeted therapies in cancer treatment, therapy-induced resistance remains a major obstacle to a complete cure. Tumor cells evade treatments and relapse via phenotypic switching driven by intrinsic or induced cell plasticity. Several reversible mechanisms have been proposed to circumvent tumor cell plasticity, including epigenetic modifications, regulation of transcription factors, activation or suppression of key signaling pathways, as well as modification of the tumor environment. Epithelial-to-mesenchymal transition, tumor cell and cancer stem cell formation also serve as roads towards tumor cell plasticity. Corresponding treatment strategies have recently been developed that either target plasticity-related mechanisms or employ combination treatments. In this review, we delineate the formation of tumor cell plasticity and its manipulation of tumor evasion from targeted therapy. We discuss the non-genetic mechanisms of targeted drug-induced tumor cell plasticity in various types of tumors and provide insights into the contribution of tumor cell plasticity to acquired drug resistance. New therapeutic strategies such as inhibition or reversal of tumor cell plasticity are also presented. We also discuss the multitude of clinical trials that are ongoing worldwide with the intention of improving clinical outcomes. These advances provide a direction for developing novel therapeutic strategies and combination therapy regimens that target tumor cell plasticity.

show abstract

“…Immune-inflamed tumors are most likely to respond to ICIs, immune-excluded tumors may require additional approaches to overcome barriers, and immune-desert tumors often necessitate innovative combination therapies to prime the immune response 30 . Therefore, the combination of immunotherapies with repurposed agents is increasingly viewed as a potential approach to improve efficacy and represents a future direction for tumor treatment 31,32 .…”

Section: Tme Phenotype and The Impact On Immunotherapymentioning

confidence: 99%

Repurposing drugs for solid tumor treatment: focus on immune checkpoint inhibitors

Liu,

Li,

Qin

et al. 2023

Cancer Biol Med

View full text Add to dashboard Cite

Cancer remains a significant global health challenge with limited treatment options beyond systemic therapies, such as chemotherapy, radiotherapy, and molecular targeted therapy. Immunotherapy has emerged as a promising therapeutic modality but the efficacy has plateaued, which therefore provides limited benefits to patients with cancer. Identification of more effective approaches to improve patient outcomes and extend survival are urgently needed. Drug repurposing has emerged as an attractive strategy for drug development and has recently garnered considerable interest. This review comprehensively analyses the efficacy of various repurposed drugs, such as transforming growth factor-beta (TGF-β) inhibitors, metformin, receptor activator of nuclear factor-κB ligand (RANKL) inhibitors, granulocyte macrophage colony-stimulating factor (GM-CSF), thymosin α1 (Tα1), aspirin, and bisphosphonate, in tumorigenesis with a specific focus on their impact on tumor immunology and immunotherapy. Additionally, we present a concise overview of the current preclinical and clinical studies investigating the potential therapeutic synergies achieved by combining these agents with immune checkpoint inhibitors.

show abstract

Multi-target combinatory strategy to overcome tumor immune escape

Cited by 15 publications

References 46 publications

Frontiers and future of immunotherapy for pancreatic cancer: from molecular mechanisms to clinical application

Frontiers and future of immunotherapy for pancreatic cancer: from molecular mechanisms to clinical application

Tumor cell plasticity in targeted therapy-induced resistance: mechanisms and new strategies

Repurposing drugs for solid tumor treatment: focus on immune checkpoint inhibitors

Contact Info

Product

Resources

About